WO2007086573A1 - Agent pour empêcher ou guérir une maladie causée par une infection par candida, et composition orale - Google Patents

Agent pour empêcher ou guérir une maladie causée par une infection par candida, et composition orale Download PDF

Info

Publication number
WO2007086573A1
WO2007086573A1 PCT/JP2007/051465 JP2007051465W WO2007086573A1 WO 2007086573 A1 WO2007086573 A1 WO 2007086573A1 JP 2007051465 W JP2007051465 W JP 2007051465W WO 2007086573 A1 WO2007086573 A1 WO 2007086573A1
Authority
WO
WIPO (PCT)
Prior art keywords
plant
power
carrot
bifidobacteria
cruciferous
Prior art date
Application number
PCT/JP2007/051465
Other languages
English (en)
Japanese (ja)
Inventor
Atsushi Ishikado
Hirohisa Suido
Takehiko Sato
Taketoshi Makino
Original Assignee
Sunstar Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sunstar Inc. filed Critical Sunstar Inc.
Priority to JP2007556044A priority Critical patent/JP5328158B2/ja
Publication of WO2007086573A1 publication Critical patent/WO2007086573A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/31—Brassicaceae or Cruciferae (Mustard family), e.g. broccoli, cabbage or kohlrabi
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Definitions

  • the present invention relates to a technique for promoting IFN- ⁇ production by using a bifidobacteria fermented product of a cruciferous plant and stimulating the immunity of a living body, as well as diseases based on Candida infection, for example, tomato skin
  • the present invention relates to a technique for preventing or improving allergic diseases such as inflammation, periodontal disease, dental caries, stomatitis, glossitis, oral infections, swallowing pneumonia, and candidiasis such as vaginitis.
  • Candida albicans Bacteria belonging to the genus Candida are often detected in the oral cavity, vagina, intestinal tract and skin of healthy individuals, with Candida albicans being the representative.
  • Candidiasis is an opportunistic infection that is often caused by these bacteria in various parts of the body when host resistance is attenuated.
  • Candidiasis is also recognized as one of the fungal complications caused by antibiotics. For example, in mucous membranes and skin, it causes wrinkles at the oral site, glossitis, mouth erosion, candidal granulation, vaginal erosion in the vagina.
  • the respiratory tract exhibits chronic bronchitis, bronchial asthma, and bronchiectasis-like symptoms.
  • Candida infections expands and causes systemic infections such as sepsis, endocarditis, meningitis (dental microbiology, dentistry and publishing, 1981, 408-412; Pathogenic microbiology, dentistry and medicine publication, 1981, 515-520; clinical and microorganisms, 28 (2), 2001, 195-199).
  • Candida is also associated with periodontal disease (Crit. Rev. Oral Biol. Med., 14 (2), 128-137, 2003; J. Periodontal Res. , 40 (6), 446-452, 2005), plaques containing Candida spp. Attached to dentures can cause stomatitis, caries and periodontal disease not only with oral candidiasis. (See J. Dent., 26 (4), 299-304, 1998; Japanese Journal of Medical Mycology, 46 (4), 233-242, 2005), and may be related to swallowing pneumonia (See J. Periodontol, 76 (11 Suppl), 2154-2160, 2005).
  • IFN-y interferon-gamma
  • Thl cells CD4-positive sputum cells
  • T cells NK cells
  • an object of the present invention is to provide a technique for preventing or ameliorating a disease based on Candida infection, a technique for immunostimulation, and a technique for promoting IFN-y production. Means for solving the problem
  • the present inventor is obtained by fermenting a cruciferous plant and at least one selected plant with carrot power by bifidobacteria.
  • the present inventors have found that a fermented product is useful for preventing or ameliorating a disease based on Candida infection and promoting IFN-7 production, thereby completing the present invention.
  • the present invention relates to the following preventive or ameliorating agent, oral composition and immunostimulator.
  • Item 1 A cruciferous plant and a carrot power A group power that prevents or ameliorates a disease based on Candida infection containing a bifidobacterial fermentation product of at least one selected plant.
  • Item 2. The agent for preventing or ameliorating a disease based on Candida infection according to Item 1, wherein the bifidobacteria is bifidobatterium longum.
  • the cruciferous plant and the carrot power group power The agent for preventing or improving diseases based on Candida infection according to Item 1, wherein at least one plant selected is a cruciferous vegetable Item 4.
  • Cruciferous plant and carrot power at least one plant selected is broccoli, cabbage, kale, cauliflower, takana, oily, radish, radish, radish leaves, Nozawana and Komatsuna Item 2.
  • Item 5 The prescription according to Item 1, wherein the disease based on Candida infection is allergic disease, atopic dermatitis, periodontal disease, dental caries, stomatitis, glossitis, oral infection, swallowing pneumonia or vaginitis Preventing or improving agent.
  • the disease based on Candida infection is allergic disease, atopic dermatitis, periodontal disease, dental caries, stomatitis, glossitis, oral infection, swallowing pneumonia or vaginitis Preventing or improving agent.
  • Item 6 A cruciferous plant and a carrot power group power An oral composition for preventing or ameliorating a disease based on Candida infection containing a bifidobacteria fermentation product of at least one selected plant.
  • Item 7 The oral composition according to Item 6, wherein the bifidobacteria is bifidobatterium 'longum.
  • Item 8 The oral composition according to item 6, wherein at least one selected plant is a cruciferous vegetable.
  • Cruciferous plant and carrot power at least one plant selected is broccoli, cabbage, kale, cauliflower, high vegetable, oily, radish, radish, radish leaf, Nozawana and Komatsuna Item 7.
  • Item 10 The oral cavity according to Item 6, wherein the disease based on Candida infection is allergic disease, atopic dermatitis, periodontal disease, dental caries, stomatitis, glossitis, oral infection, swallowing pneumonia or vaginitis Composition.
  • the disease based on Candida infection is allergic disease, atopic dermatitis, periodontal disease, dental caries, stomatitis, glossitis, oral infection, swallowing pneumonia or vaginitis Composition.
  • Item 11 A cruciferous plant and a carrot strength An immunostimulant containing a bifidobacterial fermentation product of at least one selected plant.
  • Item 12 The immunostimulant according to Item 11, wherein the bifidobacteria is Bifidobatarum longum.
  • Item 13 The cruciferous plant and the carrot strength. The selected at least one plant is a cruciferous vegetable. 11. The immunostimulant according to 11.
  • the group force selected The immunostimulant according to Item 11, which is at least one kind of vegetable selected .
  • the present invention provides at least a cruciferous plant and a group power that is also carrot power is selected.
  • An IFN- ⁇ production promoter containing a bifidobacterial fermentation product of one plant may also be included.
  • the present invention provides at least a cruciferous plant and a group power that is also a carrot power.
  • a composition for suppressing infection with bacterial bacteria, for suppressing viral infection, for reducing inflammation caused by pathogenic bacteria, or for reducing inflammation markers can be included.
  • the present invention may include the following uses and compositions for external use.
  • Item ⁇ Use of cruciferous plant and carrot power for the production of an agent for preventing or ameliorating diseases based on Candida infection
  • Item ⁇ Use of cruciferous plants and carrot power for the production of an oral composition for prevention or amelioration of diseases based on Candida infection
  • Item C Cruciferous plants and carrot power for the production of immunostimulants Use of bifidobacterial fermentation products of at least one selected plant.
  • Item D Use of a Bifidobacterium fermented product of at least one plant selected from the group of cruciferous plants and carrot power for the production of an IFN- ⁇ production promoter.
  • Item V Cruciferous plant and carrot power Group power
  • Item F The composition for external use according to Item V, wherein the bifidobacteria is bifido butterium longum.
  • Item G Brassicaceae and carrot power Group power At least one plant selected The composition for external use according to Item E or F, which is a cruciferous vegetable.
  • Item H Brassicaceae plant and carrot power at least one selected plant is broccoli, cabbage, kale, cauliflower, takana, oil, radish, radish leaf, Nozawana and Komatsuna
  • Item I Items E to H for prevention or amelioration of skin or mucosal diseases based on Candida infection! The composition for external use according to any one of the above.
  • the skin or mucosal disease based on Candida infection is allergic disease, atopic dermatitis, periodontal disease, dental caries, stomatitis, glossitis, oral infection, swallowing pneumonia or vaginitis
  • the external composition as described.
  • the present inventor is able to suppress the odor peculiar to cruciferous plants or carrots by fermenting at least one selected plant with cruciferous plants and carrot power at least one kind of plant with bifidobacteria.
  • the present invention can include the following methods. Item ⁇ . Cruciferous plant and carrot power Group power A method for reducing the odor of a cruciferous plant, wherein at least one selected plant is fermented with bifidobacteria. Item 6. The method according to Item V, wherein the bifidobacteria is Bifido Batterium longum.
  • Item M The method according to Item K or L, wherein at least one plant from which Brassicaceae and carrot power are also selected is a cruciferous vegetable.
  • Brassicaceae plant and carrot power at least one plant selected is broccoli, cabbage, kale, cauliflower, takana, oil, radish, radish, radish, Nozawana and Komatsuna
  • K to M which is at least one kind of vegetable selected.
  • the preventive or ameliorating agent for diseases based on Candida infection of the present invention (hereinafter sometimes referred to as preventive or ameliorating agent), the oral composition for preventing or ameliorating the diseases based on Candida infection (hereinafter referred to as oral composition)
  • the IFN- ⁇ production promoter, the immunostimulant and the composition for external use contain a cruciferous plant and a bifidobacteria fermentation product of at least one plant selected from the group power of carrot power.
  • the disease based on Candida infection refers to a disease caused by Candida infection.
  • the Bifidobacterium fermented product of at least one kind of plant that is also selected as a cruciferous plant and a carrot power is a fermented product of a cruciferous plant and at least one plant selected as a group power that is also a carrot power with Bifidobacterium. It also includes a culture of force bifidobacteria obtained by fermentation.
  • the bifidobacteria fermented product is, for example, a cruciferous plant and a carrot having a group power of at least one plant selected as necessary, with water in a shape suitable for fermentation, for example, puree or powder.
  • the liquid can be prepared by inoculating it with Bifidobacteria and fermenting it at an appropriate temperature.
  • Cruciferous plants and gentian plants At least one selected plant may be hydrothermally treated prior to fermentation.
  • Examples of the hot water treatment include a method of immersing at least one plant selected from a cruciferous plant and a carrot power in hot water of 90 ° C or higher, preferably 95 ° C or higher.
  • the treatment time can be appropriately set depending on the size, shape, etc. of the object to be treated. Minutes.
  • the method for inoculating the bifidobacteria is not particularly limited.
  • Cruciferous plant and carrot power group power at least one selected plant puree cruciferous plant and carrot power group power selected at least one plant puree
  • a method of mixing cells with water in which water is dissolved or suspended a method of mixing cruciferous plants and carrot strength, cutting at least one selected plant into small pieces and mixing the cells
  • a culture medium cultured in a suitable liquid medium preferably reduced skim milk supplemented with MRS broth or 0.3% yeast extract, is brought into contact with at least one plant selected from the Brassicaceae plant and the carrot power. That method (e.g., sprinkled method, a method of mixing), and the like.
  • the fermented product thus obtained is used as an active ingredient.
  • the fermentation product contains Bifidobacterium cells.
  • the fermented product contains acetic acid and lactic acid, which are presumed to be metabolites of bifidobacteria, and the ratio (weight ratio) of both is preferably about 3: 2.
  • Cruciferous plant and carrot power group power At least one selected plant can be used in one kind, or two or more kinds can be used in combination.
  • Avra Examples of rapeseed plants include cruciferous vegetables such as broccoli, cabbage, kale, cauliflower, takana, oilseed, brute, radish, radish leaf, Nozawana, and komatsuna, and broccoli is preferred.
  • cabbage, kale, cauliflower, and more preferred are broccoli, cabbage, canore.
  • At least one plant from which cruciferous plants and carrot powers are selected can be used in the whole plant, that is, any part of the plant, and in particular, an edible part is used. Use it preferably.
  • Bifidobacteria are bacteria belonging to the genus Bifidobacterium.
  • Bifido Batterium 'Longham B. longum
  • Bifido Batterium' Infantis B. infantis
  • Bifido Batterium ' B. breve
  • Bifido Batterium 'B. adolescentis Bifido Bacterium' B. pseudolongum
  • Bifido Batterium 'Lactum B.
  • lactis)' is preferred, and preferred are Bifido Batterium 'Longham, Bifido Batterium' Infantice, Bifidobacterium 'brebe, Bifido Batterium' Adrecent scent, More preferred is Bifido butterium 'longum.
  • the fermentation process It is possible to ferment even if the number of bifidobacteria inoculated per lg of at least one kind of plant selected as cruciferous plant and carrot power is 1 10 6 or more, preferably 10 7 to 10 9 .
  • the pH of the fermentation solution gradually decreases.
  • fermentation is preferably carried out until the pH is 4.8 or less.
  • fermentation can be performed by either aerobic fermentation or anaerobic fermentation, preferably anaerobic fermentation. In the case of aerobic fermentation, stationary fermentation is preferable to stirring fermentation.
  • the fermentation temperature by bifidobacteria in the fermentation process is usually 15 to 40 ° C, preferably 30 to 37 ° C, and the fermentation time is usually 5 to 200 hours, preferably 24 to 72 hours.
  • At least one plant selected from the cruciferous plant and -Ginseng as the starting material and bifidobacteria at least one plant selected from the cruciferous plant and -Ginseng as the starting material and bifidobacteria, glucose, sucrose, fructose, oligosaccharides, amino acids , Peptides, vitamins, yeast extract, edible surfactants, etc.
  • glucose, peptides and yeast extract Since growth is promoted and fermentation is promoted, it is preferable to add them.
  • the bifidobacterial fermentation product preferably contains bacterial cells as described above.
  • the number of bacterial cells contained in the Bifidobacterium fermented product is preferably io 7 to io 1C) .
  • Methods for killing cells include methods such as heating, heat drying, and acid addition. Examples of sterilization include heat sterilization such as heating at 90 ° C for 10 minutes.
  • the bifidobacteria fermented product may be subjected to treatments such as freeze-drying and spray-drying as required, and may be in various forms.
  • the liquid bifidobacterial fermentation product contained in the composition for external use of the present invention utilizes the liquid produced in the above bifidobacterial fermentation.
  • liquid bifidobacteria fermentation products include fermentation supernatants obtained by centrifuging bifidobacterial fermentation products, filtrates obtained by filtering bifidobacterial fermentation products, and the like.
  • the bifidobacteria fermented product has an action to suppress infection by Candida, an immunostimulatory action, and an IFN- ⁇ production promoting action, and the amount of the ingested bifidobacteria fermented product exerts its action. As long as it is not particularly limited, adults per day, in terms of dry matter, 10 mg to l OOg force girls, 100 mg to 30 g force girls! / ⁇ .
  • the present invention contains a bifidobacterial fermentation product. For this reason, the present invention has an action to suppress infection by Candida, an immunostimulatory action, and an IFN- ⁇ production promoting action.
  • the amount of bifidobacteria fermented product contained in the preventive or ameliorating agent, oral composition, IFN- ⁇ production promoter and immunostimulator is the amount of the preventive or improving agent, oral composition, IFN- ⁇ production promoter and immunological activation.
  • the total amount of the agent is usually 0.1 to 95% by weight, preferably 0.8 to 80% by weight.
  • the amount of the liquid bifidobacteria fermented product contained in the composition for external use of the present invention is usually 0.1 to 100% by weight, preferably 0.8 to 80% by weight of the total amount.
  • the present invention can be used in the field of utilizing the effect of inhibiting the infection of Candida by the Bifidobacterium fermented product, which is an active ingredient, and is useful, for example, in preventing or ameliorating diseases based on infection with Candida. It goes without saying that candidiasis is caused by infection with Candida. In addition, since atopic diseases, periodontal diseases, oral infections, etc. are known to be associated with Candida, as described above, suppressing infection with Candida prevents these diseases. Or it is effective for improvement.
  • the preventive or ameliorating agent of the present invention oral composition
  • the product and the composition for external use are effective in preventing or improving atopic diseases, periodontal diseases, oral infections, candidiasis, caries, stomatitis and the like among diseases based on Candida infection.
  • atopic diseases include atopic dermatitis, hay fever, allergic rhinitis, and asthma.
  • Candidiasis is not limited by the site of its onset, and includes oral candidiasis, bronchial candidiasis, pulmonary candidiasis, vulva candidiasis, urinary candidiasis, vaginal candidiasis and the like.
  • the diseases based on these other Candida infections include endocarditis, meningitis, sepsis, pneumonia such as swallowing pneumonia, and the like.
  • the present invention can be used in the field of utilizing the IFN- ⁇ production promoting action and the immune activating action of the Bifidobacterium fermented product which is an active ingredient.
  • the present invention promotes IFN- ⁇ production, immune activation, immunity It is useful for normalizing the ability and improving and maintaining the body defense ability.
  • the preventive or ameliorating agent, oral composition, IFN- ⁇ production promoter and immunostimulant of the present invention contain herbs, oligosaccharides, dietary fiber, lactic acid bacteria, viable cell preparations in addition to bifidobacterial fermentation products. It is preferable to do. By containing these, the effect of prevention or improvement based on Candida infection, the promotion effect of IFN- ⁇ production, and the enhancement of the immunostimulatory effect can be expected.
  • the content of these preferable components is not particularly limited, but is 0.1 to 95% by weight, preferably 0.8, based on the total amount of the preventive or ameliorating agent, oral composition, IF ⁇ - ⁇ production promoter and immunostimulant. ⁇ 80% by weight.
  • the preventive or ameliorating agent of the present invention can be prepared by a usual method in combination with an orally or externally acceptable carrier, etc., if necessary, for a bifidobacterial fermentation product, Depending on the purpose of use, etc., solid preparations such as liquids, tablets, granules, fine granules, powders, tablets, or capsules encapsulating the liquid or solid preparations, oral sprays, troches, oral compositions, cosmetics, etc. In various forms, such as pharmaceutical compositions, as pharmaceuticals, quasi-drugs, or health foods, functional foods, structural foods, functional health foods, foods for specified health use, dietary supplements, foods for the sick, Can be used as a beverage.
  • the oral composition, IFN- ⁇ production promoter and immunostimulant of the present invention are combined with an orally acceptable carrier or the like, if necessary, for a bifidobacterial fermentation product by a conventional method.
  • an orally acceptable carrier or the like such as liquid, tablet, granule, fine granule, powder, tablet, or capsule encapsulating the liquid or solid, oral Foods and beverages in various forms such as sprays, troches, etc., as pharmaceuticals, quasi-drugs, or health foods, functional foods, structural Z functional foods, foods for specified health use, dietary supplements, foods for the sick Can be used as
  • orally acceptable carriers include excipients, diluents and the like.
  • the preventive or ameliorating agent, oral composition, IFN- ⁇ production promoter and immunostimulant can also contain various additives such as fragrances.
  • Carriers and additives include, for example, sugar alcohols (such as maltitol, xylitol, sorbitol, erythritol), lactose, sucrose, sodium chloride sodium salt, glucose, starch, carbonates (such as calcium carbonate), Kaolin, crystalline cellulose, caustic acid, methylcellulose, glycerin, sodium alginate, gum arabic, talc, phosphates (monohydrogen phosphate, calcium hydrogen phosphate, sodium hydrogen phosphate, sodium hydrogen phosphate, dipotassium phosphate, dihydrate phosphate) Potassium, calcium dihydrogen phosphate, sodium dihydrogen phosphate, etc.) excipients such as calcium sulfate, calcium lactate, cacao butter, simple syrup, dextrose solution, starch solution, gelatin solution, polybulal alcohol, polybulu Ether, polybulur pyrrolidone, cross-polybul Loridone, hydroxypropylcellulose, low-
  • Lubricant sucrose fatty acid ester, sorbitan fatty acid ester, enzyme treatment Cytine, enzymatically decomposed lecithin, emulsifiers such as saponin, antioxidants such as ascorbic acid and tocopherol, acidulants such as lactic acid, citrate, dalconic acid, glutamic acid, vitamins, amino acids, lactate, kennate, dalcon Fortification agents such as acid salts, fluidizing agents such as silicon dioxide, sweeteners such as sucralose, acesulfame potassium, aspartame, glycyrrhizin, heart force oil, eucalyptus oil, keihi oil, wikiyou oil, tiyouji oil, orange oil, lemon oil, Examples include fragrances such as rose oil, fruit flavor, mint flavor, peppermint powder, dl-menthol, and 1 menthol.
  • emulsifiers such as saponin
  • antioxidants such as ascorbic acid and tocop
  • solid preparations such as tablets, tablets with ordinary coatings as necessary, such as sugar-coated tablets, gelatin-encapsulated tablets, enteric-coated tablets, film-coated tablets, double tablets, multilayer tablets, etc. be able to.
  • Capsules are prepared by mixing bifidobacteria fermentation products with the various carriers exemplified above and filling them into hard gelatin capsules, soft capsules and the like.
  • the liquid preparation may be an aqueous or oily suspension, solution, syrup, or elixir, and can be prepared according to a conventional method using ordinary carriers, additives and the like.
  • the oral composition is used to prevent or ameliorate diseases caused by Candida infection, such as allergic diseases such as atopic dermatitis, periodontal disease, dental caries, stomatitis, oral infections, etc.
  • diseases caused by Candida infection such as allergic diseases such as atopic dermatitis, periodontal disease, dental caries, stomatitis, oral infections, etc.
  • infectious diseases for prevention or improvement of infectious diseases, for prevention or improvement of intestinal diseases such as chronic fatigue syndrome, Crohn's disease, ulcerative colitis, autoimmune diseases, athlete's foot, etc. It can also be used for foods, functional foods, foods for specified health use, dietary supplements, foods for the sick, etc.
  • composition for external use of the present invention can be widely applied to cosmetic compositions, oral compositions, pharmaceuticals, quasi-drugs and the like applied to the outer skin and mucous membrane, and should be produced by a conventional method. Is possible.
  • the oral composition applied to the oral cavity is included in the external composition.
  • Suitable dosage forms for application to the skin or oral cavity include, for example, gels, pastes, creams, ointments, liniments, lotions, emulsions, powders, suspensions, aerosols, sprays, mists. Plasters, plasters, plasters, sheets and the like, preferably gels, creams, emulsions, liquids, pastes, mists, and sheets.
  • Specific forms suitable for application to the skin include lotions, emulsions, creams, cosmetics, Knock, makeup base lotion, makeup base cream, foundation, eye color, cheek color, lipstick, sunscreen and other skin care cosmetics, cleansing glow, cleansing cream, cleansing foam, face wash, body
  • skin cleansers such as shampoos, hair shampoos, hair rinses, hair cosmetics such as hair treatments, bath preparations, etc., preferably creams, cosmetic liquids, and sunscreens.
  • Specific forms suitable for application to the oral cavity include mouthwash, mouthwash, toothpaste, powder toothpaste, liquid dentifrice, oral ointment, oral paste, gel, tablet, granule, Fine granule, gummy jelly, troche, tablet, capsule, candy, chewing gum and the like are mentioned, and toothpaste, mouthwash, gummy jelly and troche are preferred.
  • the dosage of the composition for external use of the present invention is not particularly limited, and can be administered once or divided into several times a day.
  • components generally used as the composition for external use can be blended in a blending amount within a range in which the effects of the present invention are exhibited.
  • components interfacial active agent, a water-soluble polymer, sweetening agents, abrasives, humectants, coloring agents, antioxidants, metal sealing chain, preservatives, P H adjusting agent, cooling agents, fragrances , Moisturizers, UV absorbers, UV scattering agents, antioxidants, viscosity modifiers, antibacterial agents, bactericides, plant extracts, polyhydric alcohols, vitamins, liquid fats, solid fats, waxes, hydrocarbon oils Higher fatty acids, higher alcohols, synthetic ester oils, silicones and the like can be used.
  • active ingredients of the skin external preparation or oral composition can be blended in a blending amount within a range in which the effect of the present invention is exhibited.
  • active ingredients include moisturizers, ultraviolet absorbers, vitamins, animal and plant extract ingredients, anti-inflammatory agents, whitening agents, vasodilators, astringents, refreshing agents, hormone agents, wrinkle formation inhibitors, and fat degradation.
  • Agents, hair restorers, antiplasmin agents, etc. can be used.
  • bacteria such as lactic acid bacteria and bifidobacteria can also be added to the composition for external use of the present invention.
  • the present invention includes a method for reducing the odor of a cruciferous plant, characterized by fermenting a cruciferous plant and at least one plant selected as a carrot power also with bifidobacteria. sell.
  • This is a cruciferous plant and carrot power group power selected Fermentation of at least one plant with Bifidobacteria suppresses the odor of cruciferous plants and carrots at least one selected plant, especially the odor generated when the plant is crushed It is based on the knowledge that.
  • the conditions for fermentation are the same as described above.
  • the present invention has an action of suppressing infection with Candida, and prevents diseases caused by Candida infection, in particular, atopic diseases such as atopic dermatitis, periodontal disease, oral infection and candidiasis. Or it is effective for improvement. Furthermore, the present invention has an effect of promoting IFN- ⁇ production, and is effective in immune immunity activation, normalization of immune ability, and improvement and maintenance of biological defense ability.
  • FIG. 1 is a graph showing the test results (average survival days) obtained in Test Example 1.
  • FIG. 2 is a graph showing test results (number of surviving individuals) obtained in Test Example 1.
  • FIG. 3 is a graph showing the test results (average survival days) obtained in Test Example 2.
  • FIG. 4 is a graph showing the test results (IFN- ⁇ production amount) obtained in Test Example 5.
  • Example 1 Preparation of Bifidobacterium fermented broccoli
  • Bifido Batterium 'Longum BL1 was cultured for 2 days at 37 ° C in MRS broth (Difco). Separately, edible part of broccoli is cut into approximately 3 cm square, blanched in hot water at 90 ° C or higher for 1 minute, and then blown by hot air drying at approximately 90 ° C. A dried Roccoli was obtained. This dried broccoli was pulverized with a pulverizer to obtain a dried broccoli powder. This broccoli dry powder was suspended and mixed in distilled water at a ratio of 10% by weight to prepare a 10% broccoli powder. Add 5% by weight of the previous bifidobacteria culture to this 10% procolli powder, and incubate for 2 days. [0044] Test Example 1: Candida infection suppression test 1
  • Broccoli powder, Bifidobatterum longum BL1 powder, mixture of Broccoli powder and Bifidobatterum 'Longum BL1 cell powder, and broccoli Bifidobacteria prepared in Example 1 A sample obtained by freeze-drying the fermented product was used as a sample. Each sample was given to mice a day, 200 mg (broccoli powder), 140 mg (broth powder), 340 mg (broccoli and mixed powder) and 200 mg (broccoli bifidobacteria) per kg body weight. Fermentation) was administered orally for 7 days.
  • G-CSF granulocyte growth-promoting factor
  • Example 2 Bifidobacterium fermented cabbage
  • a dried cabbage powder was obtained in the same manner as in Example 1 from the edible portion of the cabbage.
  • the dried cabbage powder was fermented under the same conditions as in Example 1 using bified pacterium longum BL1 to obtain a bifidobacteria fermented cabbage.
  • One broccoli was fermented under the same conditions as in Example 1 except that Bifidobacteria was replaced with ratatobacillus pentosus VS10 strain, and a broccoli-one lactic acid bacteria fermentation product was obtained.
  • skim milk 10% aqueous solution (containing 0.3% yeast extract)
  • a bifidobacteria fermented product of skim milk was obtained under the same conditions as in Example 1 using bifluid pacterium longum BL1.
  • Test Example 2 Candida infection suppression test 2
  • Example 1 A Candida infection inhibition test was conducted in the same manner as in Test Example 1 except that the sample obtained in Example 1 was replaced with the sample obtained in Example 2, Comparative Example 1 and Comparative Example 2.
  • Figure 3 shows the results. Compared with the control group, a statistically significant increase in the number of days of survival was observed in the group fed with the cabbage bifidobacteria (BL1) fermented product (heat-treated), but broccoli lactic acid bacteria (VS10) There was no statistically significant increase in survival days for fermented products and bifidobacteria (BL1) fermented skim milk.
  • BL1 cabbage bifidobacteria
  • VS10 broccoli lactic acid bacteria
  • a 10% broccoli powder solution was centrifuged (10000 rpm, 10 minutes) to obtain a broccoli powder solution (abbreviated as Br).
  • a certain amount of TSB-Y Broth (not adjusted to pH and adjusted to pH 7.0) to these samples, and add 5% by weight of the aforementioned P.gingivalis and S.mutans bacterial solution to 37 ° C.
  • Bacterial growth (turbidity) in the culture medium was measured at a wavelength of 660 °, and the growth inhibitory effect of BFB and Br on oral bacteria was the ratio when the turbidity of the control with TSB-Y broth alone was 100% ( ( ⁇ OD660%) was examined.
  • the numerical value of the result is expressed as a percentage of the turbidity of the control, that is, the growth rate when the control is 100%.
  • BFB inhibited the growth of these bacteria in a concentration-dependent manner.
  • S. aureus Stpaphylococcus aureus IFO 13726 and Escherichia coli IFO 3972 were cultured in Trypticase Soy broth (Difco: TSB) at 37 ° C for 24 hours.
  • S. aureus and E. coli were added to TSB supplemented with a certain amount of broccoli bifidobacteria fermentation supernatant (BFB) and 10% broccoli powder supernatant (Br) prepared as in Test Example 3. 1% of the bacterial solution was inoculated and cultured at 37 ° C for 8 hours.
  • Bacterial growth (turbidity) in the culture medium was measured at a wavelength of 660 ⁇ m, and the growth inhibitory effect of BFB and Br on these bacteria was the ratio when the turbidity of the TSB-only control was 100% ( ⁇ OD660% ).
  • S. aureus is associated with atopic dermatitis, skin irritation, and itching! /. Therefore, by applying BFB and a preparation containing BFB to the skin, these diseases and skin This is thought to be helpful in reducing or improving symptoms.
  • E. coli is related to intestinal diseases such as hemorrhagic colitis, food poisoning, and diarrhea, so administration of BFB and a preparation containing BFB to the affected area reduces or improves these diseases and symptoms. It is thought that it is useful.
  • Broccoli puree, Bifidobatterum 'longum BL1 and Bifidobacterium fermented products of broccoli puree were prepared by the method described below, and these were used as test samples.
  • PBS solution test sample solution
  • containing each test sample was added to mononuclear cells collected from human blood, and the amount of IFN-y produced by mononuclear cells was measured.
  • 10 ⁇ L of PBS (-) was used as a control. Details of the test sample, measurement method, etc. are shown below.
  • the edible part of broccoli was cut into 5-8 centimeter squares and sterilized by heating in hot water at 98 ° C or higher for 10 minutes, and broccoli puree was obtained using commitolol.
  • the obtained broccoli puree lg was dispersed in 10 mL of PBS (-) solution to prepare a test sample solution of broccoli puree.
  • Broccoli puree was obtained in the same manner as in the preparation of broccoli puree. Put the resulting puree into a heat-resistant glass bottle, and add the culture solution of bifudium bacterium longum BL1 obtained in the same manner as in Example 1 so that the number of bacteria per 1g of puree is 1 X 10 7. I was ashamed. Fermented at 36 ° C for 24 hours. The number of bacteria after fermentation was 6.2 X 10 8 per lg fermented product . This fermented product was heat-sterilized at 98 ° C or higher for 10 minutes. The obtained heat-sterilized processed product lg was dispersed in 10 mL of PBS (-) solution to prepare a test sample solution of broccoli puree bifidobacteria fermentation product.
  • Human peripheral blood was collected into a heparin blood collection tube (10 mL).
  • the obtained blood was diluted 2-fold with PBS (—).
  • the obtained diluted solution was gently overlaid with 15 mL of FiccoU-Conray solution so as not to disturb the interface!
  • PBMC Peripheral Blood Mononuclear Cells
  • a sufficient amount of PBS (—) was added to this fraction, and centrifuged with the centrifuge (240 ⁇ g, room temperature, 10 minutes), and the supernatant was removed.
  • PBS (—) was added to the precipitated PBMC, centrifuged (160 ⁇ g, room temperature, 10 minutes), and the supernatant was removed. Further, PBS (—) was added to the precipitated PBMC, followed by centrifugation (160 ⁇ g, room temperature, 10 minutes), and the supernatant was removed.
  • RPMI1640-10% FBS-1% Antibiotic- Antimycotic was added to the obtained PBMC, and the cell concentration was adjusted to 1.0 ⁇ 10 6 ZmL. The obtained cell solution was seeded on a 12 well plate (1.0 ml each) (1.0 10 6 7 wells). Each test sample solution was added to each well and cultured for 24 hours, and then the culture supernatant was collected.
  • the broccoli puree BL1 fermented product is higher in IFN- ⁇ than the control, broccoli puree, bifido butterium 'longum BL1 and broccoli puree + BL1 test samples. Production promoting effect was shown. Since IFN- ⁇ has a physiological activity that activates the immune system, BL1 fermented broccoli puree is highly immune. It was strongly suggested to have an activation effect.
  • Test Example 6 Reduction of Fuki by bifidobacteria fermentation
  • the edible portion of cabbage was pureed with a food processor and then processed at a temperature of 95 ° C by microwave heating using a microwave oven. Cool it to 37 ° C, inoculate 5% by weight of cabbage starter with bifud butteryum longum BL1 prepared with reduced skim milk with 0.3% yeast extract and ferment at 37 ° C for 30 hours. The bifidobacteria fermented cabbage was obtained. The edible part of kale was treated in the same manner as cabbage to obtain kale bifidobacteria fermentation. Until the inoculation with bifidobacteria, unfermented processed products similarly prepared were prepared for cabbage and kale. Table 4 shows the results of numerical evaluation of the odor preference of the four types of samples using a 5-person sensory evaluation panel.
  • the criteria for the 5-point score are as follows.
  • This sterile broccoli one-part, after uniformly stirring the starter 0.3% yeast extract added reconstituted skim milk Biff prepared by id Bata Terry ⁇ arm 'longum BL1 to 5 weight 0/0 ⁇ Ka ⁇ , at 37 ° C for Then, it was allowed to stand for 24 hours and fermented to obtain a Bifidobacterium fermented product of broccoli puree.
  • This product contained Bifidobacteria at a concentration of 2 X 10 7 Zg.
  • a soft drink containing fruit juice having the composition shown in Table 5 was prepared using the bifidobacteria fermented product of this purecly puree. Preparation was carried out by stirring, mixing and dissolving all raw materials in purified water, sterilizing at 95 ° C for 1 minute, filling the can in 190 g, and then cooling in cold water.
  • the edible portion of kale was chopped into approximately 2 centimeter squares, subjected to a bleaching treatment in hot water at 95 ° C or higher for 1 minute, and then dried with a hot air at about 90 ° C to obtain a dried kale.
  • the dried kale was pulverized by a pulverizer to obtain dry kale powder.
  • 85 parts by weight of purified water was added to 15 parts by weight of the dried kale and mixed with stirring. The mixture was sterilized by heating at 95 ° C for 5 minutes and then cooled to 37 ° C.
  • This sterile kale solution after stirring uniformly to starter 5 wt 0/0 added Caro Biff id prepared butter terry ⁇ arm 'bifidum BB2 with 0.3% yeast extract added reconstituted skim milk at 37 ° C, Fermentation was carried out by standing for 36 hours to obtain a bifidobacteria fermentation solution of kale powder.
  • This product contained bifidobacteria at a concentration of 3 X 10 7 cells / g.
  • This kale bifi 10 parts by weight of lactose and 10 parts by weight of trehalose were mixed and dissolved in 80 parts by weight of the fermentation solution of Dust fungus, and then freeze-dried and finally pulverized to obtain a powder product.
  • Powdered soft drinks having the composition shown in Table 6 were prepared using the bifidobacteria fermented fermented bacterial powder of this kale.
  • the raw materials were uniformly mixed with a V-type mixer, filled in 10g each in an aluminum laminate bouch, and hermetically sealed by heat sealing. When ingesting, drink 10g of this product by dispersing and dissolving in 200ml of cold water.
  • the cabbage edible portion was cut into approximately 2 centimeter squares, subjected to a 1-minute blanking treatment in hot water at 95 ° C or higher, processed into puree using Komitrol, and stored frozen.
  • 49 parts by weight of purified water and 1 part by weight of hydrous crystalline glucose as a fermentation substrate were added, mixed by stirring, heat-sterilized at 95 ° C for 5 minutes, and then cooled to 37 ° C.
  • This sterile cabbage solution after stirring uniformly starter 0.3% yeast extract added reconstituted skim Bifuido Batateriumu 'longum BL1 prepared in milk and 5 weight 0/0 ⁇ Ka ⁇ , at 37 ° C, 24 hours static Then, fermentation was carried out to obtain a bifidobacteria fermentation product of cabbage puree.
  • This product is, bifidobacteria has been included in the 2 X 10 8 cells / g concentration.
  • a jelly having the composition shown in Table 7 was prepared.
  • the carrots from which the skin and skin were removed were cut to a length of about 5 centimeters, blanched in hot water at 95 ° C or higher for 10 minutes, and then carrots were ground using a crusher. Further, the carrot crushed material was squeezed using a filter press, and then concentrated by an evaporator until the soluble solid content became 36% to obtain a carrot concentrated juice. On the other hand, carrots treated in the same manner up to the blanching treatment were carotened into a puree using a mascot mouth lidar to obtain carrot puree.
  • carrot juice containing fruit juice having the composition shown in Table 8 was prepared. All raw materials were stirred and mixed, sterilized at 95 ° C for 1 minute, filled with 200 ml of bottles, sealed, and cooled in cold water.
  • Gummy jelly having the composition shown in Table 9 was prepared using the broccoli I bifidobacteria fermentation product prepared in Example 3. Since this gummy jelly dissolves gradually in the oral cavity like a sputum and has a long residence time in the oral cavity, it falls under the composition of the present invention and is suitable for oral diseases.
  • Sugar was mixed with maltitol and dissolved by heating to prepare a sugar solution.
  • Gelatin that had been swollen by adding a small amount of purified water was added to the sugar solution together with other ingredients, and dissolved and mixed while stirring under heating. Further, heating was continued until the soluble solid content was 77%, and according to the starch mold method, about 5 g each was filled into the molded mold.
  • the starch After drying the gummy jelly under an atmosphere of 25 ° C and relative humidity of 50% until the soluble solid content is 80% or more, the starch is removed, and finally it is covered with a small amount of release oil and powdered oblate. Got gummy jelly.
  • the obtained broccoli puree bifidobacteria fermentation product contained bifidobacteria at a concentration of 6 ⁇ 10 8 Zg.
  • a fruit juice soft drink having the composition shown in Table 10 was prepared. The preparation was performed by stirring, mixing and dissolving all raw materials in purified water, sterilizing at 95 ° C for 1 minute, filling the can with 190 g, and then cooling in cold water.
  • the edible portion of cabbage was cut to a length of about 5 centimeters, sterilized by heating in hot water at 98 ° C or higher for 6 minutes, and then processed into a puree shape using a mascot mouthlider.
  • This cane puree was placed in a tube-type cooling device, and the puree temperature was 36-38 ° C. 180 kg of cooled puree was filled into a 200-liter polyethylene bag and stored in a drum.
  • 4 wt 0.3% starter yeast extract added bi prepared in reconstituted skim milk Huy Dubai vertical Riu arm 'longum BL1 pureed 0/0 seeded, stirred with hot water disinfected Han Domikisa, Sealed and allowed to stand at room temperature for 24 hours for fermentation.
  • Obtained key The Bépure bifidobacteria fermented product contained 4 x 10 8 Zg concentrations of bifidobacteria.
  • carrots from which the skin and skin have been removed are cut to a length of about 5 centimeters, heat-sterilized in hot water at 98 ° C or higher for 20 minutes, and then mashed using a crusher. It was processed into a puree by processing with a back-striking machine. This carrot puree was placed in a tube-type cooling device, and the puree temperature was adjusted to 36-38 ° C. 180 kg of cooled puree was filled into a 200 liter polyethylene bag and stored in a drum. When storing, inoculate 4% by weight of a starter of Bifido Butterium longum BL1 prepared with reduced skim milk with 0.3% yeast extract and stir with a hand mixer that has been sterilized with hot water, then seal. And allowed to stand at room temperature for 24 hours for fermentation. The obtained carrot puree bifidobacteria fermentation product contained bifidobacteria at a concentration of 8 ⁇ 10 8 Zg.
  • fruit juice soft drinks having the compositions shown in Table 11 were prepared.
  • the preparation was performed by stirring, mixing and dissolving all raw materials in purified water, sterilizing at 95 ° C for 1 minute, filling 200 ml of the bottle, sealing it, and cooling it in cold water.
  • a mouthwash having the composition shown in Table 13 was prepared by a conventional method.
  • a troche having the composition shown in Table 14 was prepared by a conventional method.
  • Vitamin C 10. 0
  • Bifido Batterium Longum BL1 used in this example was sold by Morinaga Milk Industry Co., Ltd. under the name Bifido Batterium 'Longham BB536. Easy. Bifid Pacterium 'Bifidum BB2' is equivalent to JCM1255, a scientific research institute, and Lactobacillus' Pentosas VS10 strain is sold by Chr. Hansen GmbH under the name Vege-Start 10. ing.
  • the present invention can be used in fields requiring prevention or amelioration of diseases based on Candida infection.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Immunology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Botany (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Gynecology & Obstetrics (AREA)
  • Cosmetics (AREA)

Abstract

L'invention concerne une technique pour activer une fonction immunitaire in vivo en favorisant une production d’IFN-Ϝ au moyen d’un produit d'une plante Brassica fermenté par un bifidobactérium, et une technique pour empêcher ou guérir une maladie causée par une infection par candida, par exemple, une maladie allergique telle qu’une dermite atopique, une candidose telle qu’une périodontose, des caries dentaires, une stomatite, une glossite, une infection orale, une pneumonie par aspiration ou une vaginite. Plus particulièrement, il s’agit d’un agent permettant d’empêcher ou de guérir une maladie causée par une infection par candida qui contient un produit fermenté par un bifidobacterium d'au moins un genre de plante sélectionnée parmi un groupe qui consiste en des plantes de Brassica et des carottes, une composition orale pour empêcher ou guérir une maladie causée par une infection par candida, un immunostimulant et similaire. Des exemples de bifidobactérium incluent Bifidobacterium longum et similaires. La plante appartenant à au moins un genre de plantes sélectionnées parmi le groupe qui comprend des plantes de Brassica et des carottes, inclut, par exemple, le brocoli, le chou pommé, le chou vert, le chou-fleur, les Brassica juncea var. integlifolia, des huiles oléagineuses de colza, la moutarde noire, les radis, les feuilles de radis, les Brassica rapa var. hakabura, les Brassica rapa var. peruviridis et similaires.
PCT/JP2007/051465 2006-01-30 2007-01-30 Agent pour empêcher ou guérir une maladie causée par une infection par candida, et composition orale WO2007086573A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2007556044A JP5328158B2 (ja) 2006-01-30 2007-01-30 カンジダ菌感染に基づく疾患の予防又は改善剤及び経口組成物

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2006021450 2006-01-30
JP2006-021450 2006-01-30

Publications (1)

Publication Number Publication Date
WO2007086573A1 true WO2007086573A1 (fr) 2007-08-02

Family

ID=38309350

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2007/051465 WO2007086573A1 (fr) 2006-01-30 2007-01-30 Agent pour empêcher ou guérir une maladie causée par une infection par candida, et composition orale

Country Status (2)

Country Link
JP (1) JP5328158B2 (fr)
WO (1) WO2007086573A1 (fr)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010030947A (ja) * 2008-07-29 2010-02-12 Asuka Corporation:Kk 天然由来化粧料用防腐剤および天然由来化粧料
JP2013103880A (ja) * 2011-11-10 2013-05-30 Sunstar Inc 抗酸化機能賦活剤
EP3016667A4 (fr) * 2013-07-05 2017-01-25 Integra Medical Inc. Compositions orales
CN109568206A (zh) * 2018-12-26 2019-04-05 株洲千金药业股份有限公司 一种专用于女性的抑菌组合物及洗液和制备方法
CN110079556A (zh) * 2019-04-24 2019-08-02 上海交通大学 一种黑大麦发酵物在减轻肺损伤及肠道菌群紊乱中的应用

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH02242667A (ja) * 1989-03-15 1990-09-27 Tokyo Tanabe Co Ltd ビフィドバクテリウム菌増殖促進剤
JPH11266860A (ja) * 1998-03-19 1999-10-05 Sunstar Inc ビフィズス菌増殖促進剤、ビフィズス菌増殖促進作用を有する食品及び食品素材並びにビフィズス菌を増殖させる方法
EP1169925A1 (fr) * 2000-06-26 2002-01-09 Sitia-Yomo S.p.A. Produits alimentaires contenant des matrix de legumes fermentes et procede de preparation
JP2005089388A (ja) * 2003-09-18 2005-04-07 Biofuerumin Seiyaku Kk 免疫賦活作用増強剤
JP2005531533A (ja) * 2002-04-08 2005-10-20 ホングリム トレーディング カンパニー リミテッド 加工処理された人参抽出物及びそれから分離されたサポニンの新規の使用
JP2006034262A (ja) * 2004-07-30 2006-02-09 Sunstar Inc 食品組成物

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0551321A (ja) * 1991-08-23 1993-03-02 Yotsuba Nyugyo Kk 免疫賦活剤
JPH11246319A (ja) * 1998-02-27 1999-09-14 Ogawa Koryo Co Ltd 抗菌抗かび剤
JP3567174B2 (ja) * 1999-12-13 2004-09-22 独立行政法人産業技術総合研究所 新規白血病細胞増殖阻害剤

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH02242667A (ja) * 1989-03-15 1990-09-27 Tokyo Tanabe Co Ltd ビフィドバクテリウム菌増殖促進剤
JPH11266860A (ja) * 1998-03-19 1999-10-05 Sunstar Inc ビフィズス菌増殖促進剤、ビフィズス菌増殖促進作用を有する食品及び食品素材並びにビフィズス菌を増殖させる方法
EP1169925A1 (fr) * 2000-06-26 2002-01-09 Sitia-Yomo S.p.A. Produits alimentaires contenant des matrix de legumes fermentes et procede de preparation
JP2005531533A (ja) * 2002-04-08 2005-10-20 ホングリム トレーディング カンパニー リミテッド 加工処理された人参抽出物及びそれから分離されたサポニンの新規の使用
JP2005089388A (ja) * 2003-09-18 2005-04-07 Biofuerumin Seiyaku Kk 免疫賦活作用増強剤
JP2006034262A (ja) * 2004-07-30 2006-02-09 Sunstar Inc 食品組成物

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
BRUNO F.A. ET AL.: "INHIBITION OF PATHOGENIC AND PUTREFACTIVE MICROORGANISMS BY BIFIDOBACTERIUM SP", MILCHWISSENSCHAFT, vol. 57, no. 11-12, 2002, pages 617 - 621, XP003017959 *
KUMEMURA M. ET AL.: "Prediococcus pentosaceus no Hito ni Okeru Daicho Totatsusei oyobi Hakko Yasai Inryo Sesshu ga Kenko Seijin no Chonai Saikinfunso ni Oyobosu Eikyo", JOURNAL OF INTESTINAL MICROBIOLOGY, vol. 16, no. 2, 2002, pages 139 - 143, XP003017963 *
TAMURA Y.: "Chiryo to Chonai Saikinso Bifidus-kin o Fuyasu Hoho", THE JOURNAL OF PEDIATRIC PRATICE, vol. 47, no. 5, 1984, pages 717 - 722, XP003017960 *
TAMURA Z. ET AL.: "A PROBABLE STRUCTURE OF THE BIFIDUSFACTOR IN CARROT ROOT", CHEM. PHARM. BULL., vol. 14, no. 10, 1966, pages 1191, XP003017962 *
USAMI A. ET AL.: "Bifidus-kin no Ikusei ni Oyobosu pantethine no Koka", NIPPON NOGEI KAGAKU KAISHI, vol. 55, no. 6, 1981, pages 499 - 501, XP003017961 *

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010030947A (ja) * 2008-07-29 2010-02-12 Asuka Corporation:Kk 天然由来化粧料用防腐剤および天然由来化粧料
JP2013103880A (ja) * 2011-11-10 2013-05-30 Sunstar Inc 抗酸化機能賦活剤
EP3016667A4 (fr) * 2013-07-05 2017-01-25 Integra Medical Inc. Compositions orales
US10857090B2 (en) 2013-07-05 2020-12-08 Stellar Biome Inc. Oral compositions
CN109568206A (zh) * 2018-12-26 2019-04-05 株洲千金药业股份有限公司 一种专用于女性的抑菌组合物及洗液和制备方法
CN109568206B (zh) * 2018-12-26 2022-07-19 株洲千金药业股份有限公司 一种专用于女性的抑菌组合物及洗液和制备方法
CN110079556A (zh) * 2019-04-24 2019-08-02 上海交通大学 一种黑大麦发酵物在减轻肺损伤及肠道菌群紊乱中的应用
CN110079556B (zh) * 2019-04-24 2023-01-06 上海交通大学 一种黑大麦发酵物在减轻肺损伤及肠道菌群紊乱中的应用

Also Published As

Publication number Publication date
JP5328158B2 (ja) 2013-10-30
JPWO2007086573A1 (ja) 2009-06-25

Similar Documents

Publication Publication Date Title
JP5199551B2 (ja) カンジダ菌感染に基づく疾患の予防又は改善剤
JP5001847B2 (ja) セロオリゴ糖含有組成物
JP5954828B2 (ja) 皮膚状態の改善用組成物
US9314490B2 (en) Biological effects of compositions of rosmarinic acid
WO2007018124A1 (fr) Agent améliorant la production de collagène et utilisation de celui-ci
WO2012002322A1 (fr) Agent d'amélioration des propriétés cutanées, destiné à être administré par voie orale
JP4492956B2 (ja) アセロラ発酵物
KR101975671B1 (ko) 유산균의 유크림 발효액을 유효성분으로 포함하는 아토피 피부염의 예방 및 개선용 조성물
EP3318263B1 (fr) Composition antioxydante et composition pour l'amélioration d'états de la peau
JP2008179601A (ja) ラクトバチルス属菌を含む美容組成物
CN113925923B (zh) 一种抗痘美白的复合益生菌组合物及其制备方法
JP2006094853A (ja) ニンニクから得られる発酵物
JP5328158B2 (ja) カンジダ菌感染に基づく疾患の予防又は改善剤及び経口組成物
JP7383120B2 (ja) 皮膚状態改善用組成物
KR20100137242A (ko) 락토바실러스 속의 젖산균으로 발효된 버섯 발효 추출물 및 이를 함유하는 조성물
KR20200028627A (ko) 락토바실러스 루테리 제제를 이용한 피부개선용 조성물
EP1064855A1 (fr) Aliments, traitements medicaux et methodes visant a favoriser la croissance de (lactobacillus bifidus), a prevenir les allergies et a reduire le taux de cholesterol chez l'homme
KR102465484B1 (ko) 엔테로코커스 패칼리스 사균체를 유효성분으로 함유하는 비만 또는 비만으로부터 유도된 대사증후군의 예방 또는 치료용 조성물
EP4165220B1 (fr) Composition probiotique et ses utilisations contre les infections candida
KR101878525B1 (ko) Qol 개선 또는 지속제
KR102297957B1 (ko) 흑마늘 추출물을 유효성분으로 함유하는 여드름 또는 아토피 피부염의 예방, 개선 및 치료용 조성물
US20030165557A1 (en) Food, medicine and method relating to Bifidobacterium proliferation promoting action, allergy preventive action and human cholesterol lowering action
EP3019037B1 (fr) Composition orale comprenant l. rhamnosus gg pour utilisation dans la prevention et/ou le traitement de herpes labialis
JP4326905B2 (ja) 色素沈着抑制剤
KR20170107149A (ko) 카르노스산을 이용한 치아우식증 및 치주질환 개선용 조성물

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2007556044

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 07713720

Country of ref document: EP

Kind code of ref document: A1